×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EVOK – evoke pharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EVOK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/1
07:58 pm
evok
Halper Sadeh LLC Encourages EVOK, FSFG, BRY Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages EVOK, FSFG, BRY Shareholders to Contact the Firm to Discuss Their Rights
11/18
12:20 pm
evok
Halper Sadeh LLC Encourages AXTA, COMP, EVOK, JTAI Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages AXTA, COMP, EVOK, JTAI Shareholders to Contact the Firm to Discuss Their Rights
11/17
08:30 pm
evok
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-COMP, HFWA, EVOK, and JTAI
Low
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-COMP, HFWA, EVOK, and JTAI
11/13
07:40 am
evok
Evoke Pharma GAAP EPS of -$0.45, revenue of $4.28M [Seeking Alpha]
Low
Report
Evoke Pharma GAAP EPS of -$0.45, revenue of $4.28M [Seeking Alpha]
11/13
07:11 am
evok
Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/13
07:00 am
evok
Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Neutral
Report
Evoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update
11/6
11:12 am
evok
Evoke Pharma (NASDAQ:EVOK) was downgraded by analysts at Laidlaw from a "buy" rating to a "hold" rating.
Low
Report
Evoke Pharma (NASDAQ:EVOK) was downgraded by analysts at Laidlaw from a "buy" rating to a "hold" rating.
11/5
12:40 pm
evok
Halper Sadeh LLC Encourages HBAN, FFWM, EVOK Shareholders to Contact the Firm to Discuss Their Rights
Low
Report
Halper Sadeh LLC Encourages HBAN, FFWM, EVOK Shareholders to Contact the Firm to Discuss Their Rights
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/17
06:49 am
evok
Form SC 14D9 Evoke Pharma Inc Filed by: Evoke Pharma Inc
Low
Report
Form SC 14D9 Evoke Pharma Inc Filed by: Evoke Pharma Inc
11/17
06:08 am
evok
Form SC TO-T Evoke Pharma Inc Filed by: QOL Medical, LLC
Low
Report
Form SC TO-T Evoke Pharma Inc Filed by: QOL Medical, LLC
11/13
07:17 am
evok
Form SC14D9C Evoke Pharma Inc Filed by: Evoke Pharma Inc
Low
Report
Form SC14D9C Evoke Pharma Inc Filed by: Evoke Pharma Inc
11/13
07:05 am
evok
Form 8-K Evoke Pharma Inc For: Nov 13
Neutral
Report
Form 8-K Evoke Pharma Inc For: Nov 13
11/13
07:01 am
evok
Form 10-Q Evoke Pharma Inc For: Sep 30
Neutral
Report
Form 10-Q Evoke Pharma Inc For: Sep 30
11/12
04:41 pm
evok
Form SCHEDULE 13D Evoke Pharma Inc Filed by: Klein Roger M.
Neutral
Report
Form SCHEDULE 13D Evoke Pharma Inc Filed by: Klein Roger M.
11/7
04:59 pm
evok
Form 4 Evoke Pharma Inc For: Nov 06 Filed by: Klein Roger M.
Low
Report
Form 4 Evoke Pharma Inc For: Nov 06 Filed by: Klein Roger M.
11/6
04:11 pm
evok
Form 3 Evoke Pharma Inc For: Nov 04 Filed by: Klein Roger M.
Low
Report
Form 3 Evoke Pharma Inc For: Nov 04 Filed by: Klein Roger M.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/14
Form DEF 14A Evoke Pharma Inc For: May 27
11.6%
6/27 Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti™ NDA 6.0%
10/16 Evoke Pharma Inc (NASDAQ: EVOK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.00 price target on the stock. 5.8%
12/4 Evoke Pharma Inc (NASDAQ: EVOK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.75 price target on the stock. 3.9%
5/28 Evoke Pharma Inc (NASDAQ: EVOK) had its "hold" rating re-affirmed by analysts at HC Wainwright. 3.6%
3/3 Form 4 Evoke Pharma Inc For: Feb 28 Filed by: Gonyer David A 2.9%
5/7 Evoke Pharma Inc (NASDAQ: EVOK) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.9%
9/17 Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™ 2.1%
6/19 Form 4 Evoke Pharma Inc For: Jun 17 Filed by: Gonyer David A 2.0%
11/13 Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price 1.1%
6/27 Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti™ NDA 6.0%
10/16 Evoke Pharma Inc (NASDAQ: EVOK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.00 price target on the stock. 5.8%
12/4 Evoke Pharma Inc (NASDAQ: EVOK) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.75 price target on the stock. 3.9%
5/28 Evoke Pharma Inc (NASDAQ: EVOK) had its "hold" rating re-affirmed by analysts at HC Wainwright. 3.6%
3/3 Form 4 Evoke Pharma Inc For: Feb 28 Filed by: Gonyer David A 2.9%
5/7 Evoke Pharma Inc (NASDAQ: EVOK) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 2.9%
9/17 Evoke Pharma Completes Manufacturing of Commercial Scale Registration Batches of Gimoti™ 2.1%
6/19 Form 4 Evoke Pharma Inc For: Jun 17 Filed by: Gonyer David A 2.0%
11/13 Evoke Pharma Granted 180-Day Extension by Nasdaq Regarding Minimum Bid Price 1.1%
TOP News Decliners
1/21
Form 8-K Evoke Pharma Inc For: Jan 21
-30.0%
8/8 Form 8-K Evoke Pharma Inc For: Aug 08 -15.6%
11/18 Evoke Pharma up 32% [Seeking Alpha] -11.3%
12/20 Form 8-K Evoke Pharma Inc For: Dec 20 -10.7%
3/12 Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results -9.9%
5/8 Form 10-Q Evoke Pharma Inc For: Mar 31 -9.4%
3/26 Evoke Pharma Inc (NASDAQ: EVOK) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.5%
7/10 Evoke Pharma Inc (NASDAQ: EVOK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -6.0%
1/23 Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™ -4.3%
12/2 Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement -4.2%
8/8 Form 8-K Evoke Pharma Inc For: Aug 08 -15.6%
11/18 Evoke Pharma up 32% [Seeking Alpha] -11.3%
12/20 Form 8-K Evoke Pharma Inc For: Dec 20 -10.7%
3/12 Evoke Pharma Reports Fourth Quarter and Full Year 2019 Financial Results -9.9%
5/8 Form 10-Q Evoke Pharma Inc For: Mar 31 -9.4%
3/26 Evoke Pharma Inc (NASDAQ: EVOK) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.5%
7/10 Evoke Pharma Inc (NASDAQ: EVOK) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -6.0%
1/23 Evoke Pharma Enters Commercialization Agreement with EVERSANA Life Sciences for Gimoti™ -4.3%
12/2 Evoke Pharma Regains Compliance with Nasdaq Minimum Bid Requirement -4.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: